AMGN
Amgen Inc.
Amgen Inc. insider trading
Amgen Inc. files with the SEC as a Biological Products, (No Diagnostic Substances) company headquartered in Thousand Oaks, CA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.
From SEC filings
Recent AMGN insider transactions
3 insiders traded AMGN on the open market between Aug 06, 2026 and Aug 13, 2026 — 6 sales worth $4.1M.
- Bought
- —
- Sold
- $4.1M
- Net
- −$4.1M
- Insiders
- 3
none on a 10b5-1 plan
Khosla Rachna
SVP, Business Development
−$521.4K
Aug 13, 2026
1,252 sh · $416.43
Khosla Rachna
SVP, Business Development
−$825.1K
Aug 11, 2026
2,000 sh · $412.57
Miller Derek
SVP, Human Resources
−$832.9K
Aug 06, 2026
2,069 sh · $402.54
Miller Derek
SVP, Human Resources
−$733K
Aug 06, 2026
1,821 sh · $402.54
Grygiel Nancy A.
SVP & Cco
−$792.3K
Aug 06, 2026
1,970 sh · $402.16
Grygiel Nancy A.
SVP & Cco
−$402.2K
Aug 06, 2026
1,000 sh · $402.16
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Aug 13, 2026 | Khosla RachnaSVP, Business Development | 1,252 | $416.43 | −$521.4K |
| Aug 11, 2026 | Khosla RachnaSVP, Business Development | 2,000 | $412.57 | −$825.1K |
| Aug 06, 2026 | Miller DerekSVP, Human Resources | 2,069 | $402.54 | −$832.9K |
| Aug 06, 2026 | Miller DerekSVP, Human Resources | 1,821 | $402.54 | −$733K |
| Aug 06, 2026 | Grygiel Nancy A.SVP & Cco | 1,970 | $402.16 | −$792.3K |
| Aug 06, 2026 | Grygiel Nancy A.SVP & Cco | 1,000 | $402.16 | −$402.2K |
SEC Form 4 data, Q3 2024 to Q2 2026
AMGN insider trading by quarter
Between Jul 01, 2024 and Jun 30, 2026, 8 insiders traded AMGN on the open market: 0 purchases and 19 sales worth $50.1M. In the last four quarters alone: 0 purchases and 9 sales ($25.6M), by 5 insiders.
| Quarter | Bought | Sold | Insiders |
|---|---|---|---|
| Q2 2026 | — | −$400.5K1 sale | |
| Q1 2026 | — | −$21.1M3 sales | |
| Q4 2025 | — | −$3.7M4 sales | |
| Q3 2025 | — | −$376.3K1 sale | |
| Q2 2025 | — | −$714.2K2 sales | |
| Q1 2025 | — | −$23.8M8 sales | |
| Q4 2024 | — | — | |
| Q3 2024 | — | — |
- Largest sale
- −$11.6M of AMGN by Santos Esteban (EVP, Operations) on Feb 26, 2026.
Open-market transactions through Jun 30, 2026most recent first
Grygiel Nancy A.
SVP & Cco
−$400.5K
May 04, 2026
1,237 sh · $323.73
Santos Esteban
EVP, Operations
−$11.6M
Feb 26, 2026
30,501 sh · $379.12
Santos Esteban
EVP, Operations
−$9.2M
Feb 26, 2026
24,291 sh · $379.12
Busch Matthew C.
VP, Finance & CAO
−$375.8K
Feb 19, 2026
1,000 sh · $375.79
Grygiel Nancy A.
SVP & Cco
−$552.8K
Nov 20, 2025
1,639 sh · $337.26
Grygiel Nancy A.
SVP & Cco
−$505.9K
Nov 20, 2025
1,500 sh · $337.26
Gordon Murdo
EVP, Global Commercial Ops
−$2.3M
Nov 12, 2025
6,879 sh · $336.83
Khosla Rachna
SVP, Business Development
−$299.3K
Nov 12, 2025
890 sh · $336.24
Grygiel Nancy A.
SVP & Cco
−$376.3K
Aug 20, 2025
1,267 sh · $296.99
Khosla Rachna
SVP, Business Development
−$434.5K
Jun 05, 2025
1,500 sh · $289.68
Busch Matthew C.
VP, Finance & CAO
−$279.7K
May 02, 2025
1,000 sh · $279.69
Reese David M
EVP & Chief Technology Officer
−$7.7M
Feb 21, 2025
25,225 sh · $304.44
Reese David M
EVP & Chief Technology Officer
−$2.6M
Feb 19, 2025
8,711 sh · $293.22
Santos Esteban
EVP, Operations
−$2.6M
Feb 19, 2025
8,711 sh · $292.84
Miller Derek
SVP, Human Resources
−$447.7K
Feb 19, 2025
1,524 sh · $293.74
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| May 04, 2026 | Grygiel Nancy A.SVP & Cco | 1,237 | $323.73 | −$400.5K |
| Feb 26, 2026 | Santos EstebanEVP, Operations | 30,501 | $379.12 | −$11.6M |
| Feb 26, 2026 | Santos EstebanEVP, Operations | 24,291 | $379.12 | −$9.2M |
| Feb 19, 2026 | Busch Matthew C.VP, Finance & CAO | 1,000 | $375.79 | −$375.8K |
| Nov 20, 2025 | Grygiel Nancy A.SVP & Cco | 1,639 | $337.26 | −$552.8K |
| Nov 20, 2025 | Grygiel Nancy A.SVP & Cco | 1,500 | $337.26 | −$505.9K |
| Nov 12, 2025 | Gordon MurdoEVP, Global Commercial Ops | 6,879 | $336.83 | −$2.3M |
| Nov 12, 2025 | Khosla RachnaSVP, Business Development | 890 | $336.24 | −$299.3K |
| Aug 20, 2025 | Grygiel Nancy A.SVP & Cco | 1,267 | $296.99 | −$376.3K |
| Jun 05, 2025 | Khosla RachnaSVP, Business Development | 1,500 | $289.68 | −$434.5K |
| May 02, 2025 | Busch Matthew C.VP, Finance & CAO | 1,000 | $279.69 | −$279.7K |
| Feb 21, 2025 | Reese David MEVP & Chief Technology Officer | 25,225 | $304.44 | −$7.7M |
| Feb 19, 2025 | Reese David MEVP & Chief Technology Officer | 8,711 | $293.22 | −$2.6M |
| Feb 19, 2025 | Santos EstebanEVP, Operations | 8,711 | $292.84 | −$2.6M |
| Feb 19, 2025 | Miller DerekSVP, Human Resources | 1,524 | $293.74 | −$447.7K |
From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.
Amgen Inc. company record
- SEC industry classification
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Thousand Oaks, CA
- Incorporated in
- DE
- Listed on
- Nasdaq
- SEC Central Index Key
- 0000318154
Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.
After insiders bought AMGN
What the stock actually did in the 90 days following each open-market purchase
Don't check AMGN — let it ping you
Get told the moment an insider moves on AMGN
Pro watches Amgen Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add AMGN to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.
The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.
How to read AMGN insider activity
- Open-market purchase (code P)
- An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
- Grants and option exercises (codes A, M)
- Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
- Cluster buy
- Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.
Other Health Care tickers
Questions
- Are AMGN insiders buying or selling?
- Between Aug 06, 2026 and Aug 13, 2026, 3 Amgen Inc. insiders made no open-market purchases and 6 sales worth $4.1M, a net sale of $4.1M.
- How much AMGN stock have insiders bought and sold in the last two years?
- Between Jul 01, 2024 and Jun 30, 2026, 8 Amgen Inc. insiders made no open-market purchases and 19 sales worth $50.1M. In the four quarters to Jun 30, 2026: no purchases and 9 sales ($25.6M). The largest sale was Santos Esteban selling $11.6M on Feb 26, 2026.
- What was the largest recent AMGN insider trade?
- Miller Derek (SVP, Human Resources) sold $832.9K of AMGN stock on Aug 06, 2026 at about $402.54 a share.
- When did an insider last buy AMGN shares?
- No open-market purchase by a Amgen Inc. insider appears in the filings from Aug 06, 2026 to Aug 13, 2026 — every recorded open-market transaction in that period was a sale.
- Where does AMGN insider trading data come from?
- From the Form 4 filings Amgen Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.
Get the free Insider Brief
Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.